Article info
PDFCurrent controversy
Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials
- Correspondence to Professor Soren Holm, The University of Manchester, Manchester M13 9PL, UK; soren.holm{at}manchester.ac.uk
Citation
Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials
Publication history
- Received January 28, 2022
- Accepted May 13, 2022
- First published May 23, 2022.
Online issue publication
June 22, 2023
Article Versions
- Previous version (23 May 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Other content recommended for you
- Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
- Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
- Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir
- Learning health systems, clinical equipoise and the ethics of response adaptive randomisation
- E-therapies in England for stress, anxiety or depression: what is being used in the NHS? A survey of mental health services
- Evolving role of novel COVID-19 Medicine Delivery Units
- Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
- Early development of primary care networks in the NHS in England: a qualitative mixed-methods evaluation
- OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
- Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY